VITOSS Podium and Electronic Poster Presentations at 2008 AANS/CNS Meeting

MALVERN, Pa.--(Business Wire)--
Orthovita, Inc. (NASDAQ:VITA), a spine and orthopedic biosurgery
company, announced today an upcoming presentation and electronic
posters related to its VITOSS Bone Graft Substitute product. These
presentations will be held at the 2008 Annual Meeting of the American
Association of Neurological Surgeons/Congress of Neurological Surgeons
(AANS/CNS), Section on Disorders of the Spine and Peripheral Nerves,
held in Orlando, Florida from February 27 through March 1, 2008. These
presentations are based on research conducted independently from
Orthovita.

Oral Poster Presentation

Jeffrey McConnell, M.D., of the Pennsylvania Spine and Scoliosis
Institute at OAA Orthopaedic Specialists in Allentown, will give an
oral poster presentation of an abstract entitled, "A comparison of
Beta-TCP+BMA vs. RhBMP-2 in anterior lumbar interbody fusion: A
prospective, randomized trial with 1- year interim clinical and
radiographic outcomes."

"To my knowledge, our study represents the first direct randomized
comparison between VITOSS enriched with bone marrow aspirate and
recombinant human bone morphogenic protein in anterior lumbar fusion
procedures," said Dr. McConnell. "Our results show no difference in
radiological and clinical outcomes between the two groups. The data
from this study can help physicians choose the best bone graft
composition for an individual patient, taking both physiologic and
economic factors into consideration."

The podium presentation is scheduled for February 28, 2008, from
5:03 p.m. to 5:06 p.m. in Scientific Session II.

Poster Presentations

Neill Wright, M.D., Associate Professor in Neurological and
Orthopaedic Surgery at Washington University School of Medicine in St.
Louis, will present two electronic poster abstracts at the same
meeting.

The first abstract is entitled "A Safer Method of Anterior
Cervical Arthrodesis Using rhBMP-2 in High-Risk Patients: Safety
Profile and Fusion Outcomes in 50 Patients Treated with rhBMP-2 on a
Beta-Tricalcium Phosphate Carrier."

The second abstract is entitled "Anterior Cervical Arthrodesis
Without Autograft, Allograft, or BMP-2: 75 Patients Treated with
Beta-Tricalcium Phosphate Impregnated with Local Bone Marrow
Aspirate."

Dr. Wright started his studies about two years ago. "We were not
entirely satisfied with allograft as a replacement for autograft, and
thus were looking for an alternative," he said. "We specifically chose
VITOSS for the osteoconductive component of our graft because of its
unique structure and high porosity. In our studies, we have combined
VITOSS with either bone marrow or BMP, and obtained healing results
that are at least comparable to those we obtained with autograft."

About the Company

Orthovita is a spine and orthopedic biosurgery company with
proprietary biomaterials and biologic technologies for the development
and commercialization of synthetic, biologically active, tissue
engineering products. We develop and market synthetic-based
biomaterials products for use in spine surgery, the repair of
fractures and a broad range of clinical needs in the trauma, joint
reconstruction, revision and extremities markets. Our near-term
commercial business is based on our VITOSS(R) Bone Graft Substitute
technology platforms, which are designed to address the non-structural
bone graft market by offering synthetic alternatives to the use of
autograft or cadaver-based bone material, and VITAGEL(R) Surgical
Hemostat, which is an adherent matrix and an impermeable barrier to
blood flow. Our longer-term U.S. clinical development program is
focused on our internally developed CORTOSS(R) Bone Augmentation
Material technology platform, which is primarily designed for
injections in osteoporotic spines to treat vertebral compression
fractures. We work jointly with Kensey Nash Corporation to develop and
commercialize novel synthetic-based biomaterial products, we market
VITAGEL under a license granted by Angiotech Pharmaceuticals, Inc.,
and we continue to pursue similar relationships with other companies
in biomaterials.

Disclosure Notice

This press release may contain forward-looking statements
regarding Orthovita's current expectations of future events that
involve risks and uncertainties, including, without limitation, the
development, regulatory approval, demand and market acceptance of our
products; our ability to obtain FDA clearance for CORTOSS in the
United States; and other aspects of our business. Such statements are
based on management's current expectations and are subject to a number
of substantial risks and uncertainties that could cause actual results
or timeliness to differ materially from those addressed in the
forward-looking statements. Other factors that may cause such a
difference are listed from time to time in reports filed by the
Company with the U.S. Securities and Exchange Commission (SEC),
including but not limited to risks described in our most recently
filed Form 10-K under the caption "Risks Factors". Further information
about these and other relevant risks and uncertainties may be found in
Orthovita's filings with the SEC, all of which are available from the
SEC as well as other sources. Orthovita undertakes no obligation to
publicly update any forward-looking statements.

Orthovita, Inc.
Albert J. Pavucek, Jr.
Chief Financial Officer
610-640-1775 or 800-676-8482

Copyright Business Wire 2008